BAX 826Alternative Names: Bax-826; BAX826; Polysialylated rFVIII; PSA-FVIII - Shire/Xenetic Biosciences; PSA-rFVIII; SHP 656
Latest Information Update: 21 Nov 2016
At a glance
- Originator Baxter International; Xenetic Biosciences
- Developer Shire; Xenetic Biosciences
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
- Mechanism of Action Blood coagulation factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Haemophilia
- Phase I Haemophilia A